Creso Pharma to benefit from OTC cannabis sales in Australia
Finfeed
Archived
Sep 10, 2020
The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).
